Bromocriptine for treating hyperprolactinemia, acromegaly, and Parkinson's disease

Bromocriptine mesylate tablets contain bromocriptine, a dopamine receptor agonist derived from ergot. It is used to treat conditions caused by high prolactin levels, acromegaly (a hormonal disorder involving excess growth hormone), and symptoms of Parkinson's disease. By stimulating dopamine receptors, bromocriptine helps regulate hormone secretion and improves motor control in neurological disorders.

Bromocriptine mesylate tablets are approved for the following uses:

• Treating dysfunctions associated with hyperprolactinemia—including amenorrhea (absence of menstruation) with or without galactorrhea (milk flow), infertility, or hypogonadism—often linked to prolactin-secreting pituitary adenomas. The drug can also reduce the size of macroadenomas before surgery.
• Treating acromegaly by lowering elevated serum growth hormone levels, either alone or alongside pituitary surgery or radiation, although full normalization is uncommon.
• Managing signs and symptoms of idiopathic or postencephalitic Parkinson's disease, especially as an adjunct to levodopa treatment in patients experiencing reduced effectiveness or side effects from levodopa therapy. Bromocriptine may allow a levodopa dose reduction, helping reduce levodopa-associated complications such as dyskinesias and motor fluctuations.

Bromocriptine mesylate

Bromocriptine acts by stimulating dopamine receptors in the brain and pituitary gland. It inhibits prolactin secretion by activating dopamine receptors in the tuberoinfundibular pathway, restoring normal hormonal function in conditions caused by elevated prolactin. In acromegaly, bromocriptine lowers abnormally high growth hormone levels. For Parkinson's disease, it directly stimulates dopamine receptors in the corpus striatum, compensating for the dopamine deficiency characteristic of the disorder and improving motor symptoms.

Dosage varies depending on the condition treated and must be prescribed by a healthcare professional. Bromocriptine mesylate tablets are taken orally, recommended with food to reduce nausea. Pharmacokinetic studies show peak plasma concentration around 2.5 hours after dosing, with a half-life near 5 hours. Steady-state levels are achieved with twice-daily dosing. Specific dose adjustments based on renal or hepatic impairment have not been established; caution is advised in liver dysfunction.

Patients should follow the exact dosing instructions provided by their provider and not alter their dose without consultation.

• Hypersensitivity to bromocriptine or any components of the tablet.
• Uncontrolled hypertension.
• Sensitivity to any ergot alkaloid.
• Use during postpartum in women with a history of serious cardiovascular disease unless medically necessary; if used, cautious monitoring is necessary.

• Serious cardiovascular events including hypertension, myocardial infarction, seizures, and strokes have been reported, especially in postpartum women treated for lactation inhibition; thus, the drug is not recommended for prevention of physiological lactation or in patients with uncontrolled hypertension.
• Bromocriptine can cause somnolence and sudden sleep onset, particularly in Parkinson's patients; affected individuals should avoid driving or operating machinery.
• Symptomatic hypotension can occur, especially at treatment initiation; blood pressure should be regularly monitored, and caution taken with activities requiring alertness.
• Patients should be monitored for pleural, pericardial, or retroperitoneal fibrosis during long-term, high-dose therapy; symptoms such as unexplained pleuropulmonary issues or back pain warrant evaluation and possible drug discontinuation.
• The drug should be discontinued if severe or progressive headaches, visual disturbances, or central nervous system toxicity develop.
• Pregnancy requires special consideration; bromocriptine should be stopped if pregnancy is detected in hyperprolactinemia treatment, but may be continued with caution if medically necessary in acromegaly or Parkinson’s patients, weighing risks of hypertensive disorders of pregnancy.
• Concomitant use with other ergot alkaloids is not recommended due to risk of additive effects.

• Common side effects include nausea and vomiting, often reduced when taken with food.
• Somnolence and sudden sleep onset have been reported, mostly in Parkinson’s disease patients.
• Hypotension symptoms such as dizziness or lightheadedness may occur, especially at therapy initiation.
• Serious but rare effects reported include hypertension, seizures, stroke, myocardial infarction, pleural and pericardial effusions or fibrosis, retroperitoneal fibrosis, and visual disturbances.

Bromocriptine is metabolized mainly by CYP3A4. Strong inhibitors or substrates of CYP3A4 may increase bromocriptine levels. Additionally, bromocriptine itself inhibits CYP3A4 in vitro but not at clinically significant concentrations. Interaction with other ergot alkaloids can increase adverse effects and is not recommended.

In hyperprolactinemia treatment, bromocriptine should be discontinued upon pregnancy detection. When used for acromegaly, prolactinoma, or Parkinson's disease, continuation during pregnancy should be carefully considered; the drug should be withdrawn in women at risk for hypertensive pregnancy disorders unless medically contraindicated. Safety to mother and fetus has not been established. Postpartum use is contraindicated in women with serious cardiovascular conditions unless necessary, with careful observation.

Details on overdose manifestations and management are not provided in the supplied source.

No specific storage instructions were detailed in the provided evidence.